Nitroxyl (HNO) stimulates soluble guanylyl cyclase to suppress cardiomyocyte hypertrophy and superoxide generation.
New therapeutic targets for cardiac hypertrophy, an independent risk factor for heart failure and death, are essential. HNO is a novel redox sibling of NO• attracting considerable attention for the treatment of cardiovascular disorders, eliciting cGMP-dependent vasodilatation yet cGMP-independent po...
Main Authors: | Eliane Q Lin, Jennifer C Irvine, Anh H Cao, Amy E Alexander, Jane E Love, Ruchi Patel, Julie R McMullen, David M Kaye, Barbara K Kemp-Harper, Rebecca H Ritchie |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3323591?pdf=render |
Similar Items
-
The soluble guanylyl cyclase activator bay 58-2667 selectively limits cardiomyocyte hypertrophy.
by: Jennifer C Irvine, et al.
Published: (2012-01-01) -
Reactions of biologically important thiols with nitroxyl (HNO) and development of a HNO marker
by: Shen, Biao
Published: (2007) -
Nucleotidyl cyclase activity of particulate guanylyl cyclase A: comparison with particulate guanylyl cyclases E and F, soluble guanylyl cyclase and bacterial adenylyl cyclases CyaA and edema factor.
by: Kerstin Y Beste, et al.
Published: (2013-01-01) -
Computational Study of the Reductive Phosphine-Mediated Ligation of Nitroxyl (HNO)
by: Chung-Ying Kao, et al.
Published: (2013) -
SYNTHESIS AND PHOTOCHEMICAL STUDIES OF NEW PHOTOACTIVATABLE NITROXYL (HNO)-RELEASING COMPOUNDS
by: Rahman, Mohammad Saifur
Published: (2019)